CANDEL THERAPEUTICS - AGLATIMAGENE PLUS VALACYCLOVIR WELL TOLERATED; GRADE 3 ADVERSE EVENTS IN 13.7% OF PATIENTS

Reuters · 1d ago

Please log in to view news